News
Market and company headlines
JAGXAll
Loading
05:00-10:00Oct 212 Stories
Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder
Liquid oral crofelemer therapy is well tolerated by this patient and has demonstrated reduced needs for daily and weekly parenteral support (PS) with no significant clinical or laboratory abnormalities. CSD due to mutation of the GUCY2C gene is the third IF-related congenital enteropathy being evaluated under expanded access, in addition to pediatric microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF), for which crofelemer has demonstrated benefit in reducing weekly parenteral
Jaguar Health's Napo Pharma Announces Expanded-Access Benefit Of Crofelemer In Congenital Sodium Diarrhea Patient; Plans To File NDA For Crofelemer For MVID In Mid-2027
Mutation of the GUCY2C gene is the third IF-related congenital enteropathy, in addition to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF), for which crofelemer has demonstrated benefit in
12:00-17:00Oct 142 Stories
Jaguar Health Provides Update Regarding Special Stock Dividend
The Special Stock Dividend consists of the Company's Series R Convertible Preferred Stock (the "Preferred Stock").Nasdaq has advised the Company that its shares of common stock will trade with "due bills" representing an assignment of the right to receive the dividend from the record date of October 13, 2026 until the Ex-Dividend Date (this period of time representing the "Dividend Right Period").
Jaguar Health Provides Update On Special Stock Dividend; Nasdaq Sets October 16 Ex-Dividend Date
Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternativesJaguar's rare disease intestinal failure development program for microvillus inclusion
05:00-10:00Oct 142 Stories
Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer
The abstract presented at ACG 2026, titled The Use of Crofelemer in Reducing Ostomy Output in Patients With Type 1 Short Bowel Syndrome: An Open Label Pilot Study, can be viewed by clicking here.Patients with intestinal failure (IF), including those with short bowel syndrome or pediatric patients with MVID, cannot orally absorb adequate nutrients, electrolytes and fluids, and require lifelong total parenteral nutrition (TPN) with or without supplemental intravenous fluids, which together compris
Jaguar Health Demonstrates Recap Of Preliminary Data At American College Of Gastroenterology Annual Scientific Meeting For Its Current Trial Of Crofelemer Powder For Oral Solution In Adult Patients With Type 1 Short Bowel Syndrome With Intestinal Failure
Jaguar Health, Inc. (Nasdaq:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today provided a recap of the positive preliminary results presented on October 13, 2026 at the American College of Gastroenterology
09:00Oct 131 Story
09:00-11:00Oct 63 Stories
Jaguar Health Targets Mid-2027 MVID NDA Filing as Crofelemer Intestinal Failure Program Advances
Jaguar Health subsidiary Napo Pharmaceuticals is continuing its global crofelemer development program for rare intestinal failure diseases while preparing for a planned mid-2027 New Drug Application filing for microvillus inclusion disease. Key Investor TakeawaysJaguar Health (NASDAQ:JAGX) continues to target a mid-2027 MVID NDA filing for crofelemer powder for oral solution.
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares moved upwards by 52.5% to $7.0 during Tuesday's regular session. The company's market cap stands at $6.9 million. Option Care Health (NASDAQ:OPCH) stock
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi
04:00-09:00Oct 62 Stories
What's going on in today's pre-market session
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Jaguar Health (NASDAQ:JAGX) stock moved upwards by 34.0% to $6.34 during Tuesday's pre-market session. The company's market cap stands at $2.4 million. Option Care Health (NASDAQ:OPCH) stock rose
22:00Oct 51 Story
20:00Oct 21 Story
04:00Sep 291 Story
06:00-11:00Sep 252 Stories
Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split Float
Jaguar Health is surging on a float so thin that a handful of trades can swing the price wildly, while a rare pediatric disease program edges closer to a pivotal regulatory filing that could either validate the rally or expose how fragile it really is.
Jaguar Health Stock Surges Friday: What's Happening?
Jaguar Health is surging Friday after announcing debt-for-equity exchanges that cut debt by over $6.7 million and retired a promissory note.
04:00Sep 251 Story
10:00-12:00Sep 242 Stories
Jaguar Health Stock Slides Thursday: What's Happening?
Jaguar Health shares are sliding Thursday as equity dilution concerns weigh on the company following a debt-for-equity exchange.
Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%
Two biotech stocks are getting crushed while the sector benchmark climbs, and the reasons behind each selloff could not be more different. Understanding what separates a deliberate corporate move from pure micro-cap chaos is the key to reading both situations correctly.
05:00Sep 242 Stories
Reported Earlier: Jaguar Health Issues 547,898 Common Shares To Streeterville Capital To Retire ~$5.05M Of Outstanding Promissory Note
As previously disclosed, on November 12, 2025, Jaguar Health, Inc. (the "Company") issued and sold to Streeterville Capital, LLC ("Streeterville") a secured promissory note in the original principal
Jaguar Health Files Supplement To Offer Up To ~$9.82M Of Common Stock Under At-The-Market Offering Program
JAGUAR HEALTH, INC.Up to $9,824,188Shares of Common Stock This supplement No. 8 (this "Supplement) amends and supplements certain information contained in the prospectus supplement, dated May 23, 2024, as amended by
06:00-12:00Sep 232 Stories
Two Biotechs Get Beaten Down: Jaguar Health Collapses 59%, Viking Therapeutics Sinks 4%
Jaguar Health and Viking Therapeutics are both sinking Wednesday morning, but the forces behind each drop point in completely different directions, and the broader biotech sector is barely flinching.
Jaguar Health Stock Plunges Wednesday: What's Happening?
Jaguar Health shares are plunging Wednesday morning as profit-taking reverses an explosive Tuesday rally sparked by regulatory fee waivers.
04:00Sep 231 Story
17:00-20:00Sep 223 Stories
Jaguar Health Stock Surged 1200% on Tuesday: Here's Why JAGX Stock Is Trending After Hours
Jaguar Health shares jumped 5.19% after hours following FDA fee waivers for two of its commercialized therapies.
Jaguar Health, IONQ, Viking Therapeutics, Xanadu Quantum and Grab Holdings: Why These 5 Stocks Are on Investors' Radars Today
JAGX, IONQ, VKTX, XNDU, GRAB were among the stocks seen trending on Tuesday, Sept. 22, 2026.
09:00-13:00Sep 222 Stories
What's going on in today's session
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Jaguar Health Receives Fee Waivers from FDA
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027SAN FRANCISCO, CA / ACCESS Newswire / September 22, 2026 / (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that the U. Food and Drug Administration (FDA) has granted Napo's request for a waiver of the fee associated with the Pres
05:00Sep 221 Story
05:00-10:00Sep 152 Stories
Jaguar Health, Inc. Announces Reverse Stock Split
The Company's Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on The Nasdaq Capital Market under the symbol "JAGX". The new CUSIP number for the Company's Common Stock following the reverse stock split is 47010C854.
Jaguar Health To Effect 1-For-15 Reverse Stock Split Of Common Stock On September 17
Reverse split approved at April 2026 Special Meeting of StockholdersShares of Jaguar Health common stock to begin trading on split-adjusted basis on September 17, 2026Reverse split approved at April 2026 Special Meeting
08:00-10:00Sep 102 Stories
All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
The trial is ongoing at multiple centers in the United States, the European Union, and the United Arab Emirates. This trial is expected to support a New Drug Application (NDA) filing for the treatment of the MVID indication in mid-2027.
Jaguar Health Stock Slides Thursday: What's Happening?
Jaguar Health is trading lower Thursday as investors weigh the clinical timeline for its rare pediatric disease pipeline after an update.
05:00Sep 101 Story
13:00-18:00Sep 42 Stories
Stay updated with the stocks that are on the move in today's after-hours session.
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares increased by 10.4% to $1.7 during Friday's after-market session. The market value of their outstanding shares is at $3.8 million. Genelux (NASDAQ:GNLX) stock moved upwards by
08:00-10:00Sep 42 Stories
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Immuron (NASDAQ:IMRN) shares moved upwards by 48.2% to $1.65 during Friday's regular session. The market value of their outstanding shares is at $8.9 million. bioAffinity Technologies (NASDAQ:BIAF) shares
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)
Napo remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for pediatric rare IF diseases, including microvillus inclusion disease (MVID) and short bowel syndrome with IF (SBS-IF). In June 2026, as announced, data was presented at the 58th Annual European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) Meeting in Lille, France from ongoing investigational studies with oral liquid crofelemer
13:00Sep 11 Story
05:00-10:00Aug 262 Stories
Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
Neonorm Dog is designed to provide dog owners with access to a plant-based, non-prescription product intended to support normal stool consistency and GI fluid balance in dogs. The Neonorm franchise currently includes Neonorm Foal and Neonorm Calf, plant-based products developed to support proper hydration and bowel health in pre-weaned foals and calves.
Jaguar Health Initiates Commercial Roll Out Of Neonorm Dog
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced the initiation of the commercial launch of Neonorm Dog, a new extension of Jaguar's Neonorm franchise for companion and production animals.
13:00-20:00Aug 192 Stories
Jaguar Health, Inc. (JAGX) Q2 2026 Earnings Call Prepared Remarks Transcript
Jaguar Health, Inc. (JAGX) Q2 2026 Earnings Call August 19, 2026 4:30 PM EDTCompany ParticipantsLisa Conte - Founder, CEO, President & DirectorCarol...
Jaguar Health Reports Q2 2026 Results: Full Earnings Call Transcript
Jaguar Health (NASDAQ:JAGX) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and